65,437 trials
Endometriosis
Primary: Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment — 23.7; 62.8; 29.1; 63.8 percentage…
Stroke
Primary: Fugl Meyer Assessment on Upper Extremity (FMA-UE) — 37.03; 41.83; 38.77; 43.93 score on a scale
COVID-19
Primary: Mortality Rate — 6; 1 Participants — p=0.0318
Type 1 Diabetes Mellitus
Primary: Percentage of Time Glucose Levels Were > 180 mg/dL (10.0 mmol/L) From 6 AM to 11:59 PM — 37; 34 percentage of time
Neuralgia · Myalgia
Primary: Neuromuscular Symptoms — 36.5; 43.5; 28.5; 32.7 score on a scale — p=<0.01
Cocaine Dependency
Primary: Safety of Single Oral Doses — 0; 0; 0; 0 participants
Colon Cancer
Primary: Adenoma Detection Rate (ADR) During Colonoscopy Procedure — 43.75; 33.33 percentage of participants
15q Duplication Syndrome · CDKL5 Deficiency Disease
Primary: Percent Change From Baseline in Motor Seizure Frequency Per 28 Days During the Maintenance Period — 11.7; -23.6 percent change
Eustachian Tube Dysfunction
Primary: Latency Between mLVP and mTVP Signals — 127.26 Time in milliseconds
Breast Cancer
Primary: Count of Participants Receiving Adjuvant Radiation Therapy Via Multi-beam IMRT Using Daily 3D Position Verification — 1; 111; 4 Participants
Obesity · Dysglycemia
Primary: Fasting and 2 Hour Glucose Levels, Comparing Baseline and 12 Weeks. — -5; 3; 7; -4 mg/dl
Sickle Cell Disease · Vaso-Occlusive Crisis
Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] — 0; 4; 4; 26 Participants
Melanoma (Skin)
Primary: Safety of the Peptide Vaccines — 4; 7; 2; 1 Participants
Arthroplasty, Replacement, Hip · Arthroplasty, Replacement, Knee
Primary: Picker Patient Experience (PPE-15) Questionnaire — 13; 13; 11.1; 12.3 percentage of problem responses
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3202626 — 27.9; 36.1; 39.4 nanogram/milliliter (ng/mL)